Intrinsic value of Progenics Pharmaceuticals - PGNX

Previous Close

$5.30

  Intrinsic Value

$4.01

stock screener

  Rating & Target

sell

-24%

Previous close

$5.30

 
Intrinsic value

$4.01

 
Up/down potential

-24%

 
Rating

sell

We calculate the intrinsic value of PGNX stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.4

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  40.30
  36.77
  33.59
  30.73
  28.16
  25.84
  23.76
  21.88
  20.20
  18.68
  17.31
  16.08
  14.97
  13.97
  13.08
  12.27
  11.54
  10.89
  10.30
  9.77
  9.29
  8.86
  8.48
  8.13
  7.82
  7.53
  7.28
  7.05
  6.85
  6.66
Revenue, $m
  16
  22
  30
  39
  50
  63
  78
  95
  115
  136
  160
  185
  213
  243
  274
  308
  344
  381
  420
  461
  504
  549
  596
  644
  694
  747
  801
  857
  916
  977
Variable operating expenses, $m
  13
  17
  21
  26
  32
  39
  47
  56
  67
  79
  87
  101
  116
  132
  150
  168
  188
  208
  229
  252
  275
  300
  325
  351
  379
  407
  437
  468
  500
  533
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  13
  17
  21
  26
  32
  39
  47
  56
  67
  79
  87
  101
  116
  132
  150
  168
  188
  208
  229
  252
  275
  300
  325
  351
  379
  407
  437
  468
  500
  533
Operating income, $m
  3
  6
  9
  13
  18
  24
  31
  39
  48
  57
  73
  84
  97
  110
  125
  140
  156
  173
  191
  210
  229
  249
  271
  293
  315
  339
  364
  390
  416
  444
EBITDA, $m
  9
  12
  16
  21
  26
  33
  41
  50
  60
  72
  84
  98
  112
  128
  145
  162
  181
  201
  222
  243
  266
  289
  314
  340
  366
  394
  422
  452
  483
  515
Interest expense (income), $m
  0
  4
  4
  7
  10
  14
  19
  25
  31
  38
  47
  56
  66
  77
  89
  102
  115
  130
  145
  161
  178
  196
  214
  233
  253
  274
  296
  318
  342
  366
  391
Earnings before tax, $m
  -1
  1
  2
  3
  4
  5
  7
  8
  9
  11
  17
  18
  20
  21
  23
  25
  26
  28
  30
  32
  33
  35
  37
  39
  41
  43
  46
  48
  50
  53
Tax expense, $m
  0
  0
  1
  1
  1
  1
  2
  2
  3
  3
  4
  5
  5
  6
  6
  7
  7
  8
  8
  9
  9
  10
  10
  11
  11
  12
  12
  13
  14
  14
Net income, $m
  -1
  1
  2
  2
  3
  4
  5
  6
  7
  8
  12
  13
  14
  16
  17
  18
  19
  20
  22
  23
  24
  26
  27
  29
  30
  32
  33
  35
  37
  38

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  91
  125
  167
  218
  279
  351
  435
  530
  637
  756
  887
  1,029
  1,183
  1,349
  1,525
  1,712
  1,910
  2,118
  2,336
  2,564
  2,802
  3,050
  3,309
  3,578
  3,857
  4,148
  4,450
  4,764
  5,090
  5,429
Adjusted assets (=assets-cash), $m
  91
  125
  167
  218
  279
  351
  435
  530
  637
  756
  887
  1,029
  1,183
  1,349
  1,525
  1,712
  1,910
  2,118
  2,336
  2,564
  2,802
  3,050
  3,309
  3,578
  3,857
  4,148
  4,450
  4,764
  5,090
  5,429
Revenue / Adjusted assets
  0.176
  0.176
  0.180
  0.179
  0.179
  0.179
  0.179
  0.179
  0.181
  0.180
  0.180
  0.180
  0.180
  0.180
  0.180
  0.180
  0.180
  0.180
  0.180
  0.180
  0.180
  0.180
  0.180
  0.180
  0.180
  0.180
  0.180
  0.180
  0.180
  0.180
Average production assets, $m
  36
  49
  66
  86
  110
  138
  171
  208
  250
  297
  349
  405
  465
  530
  600
  673
  751
  833
  919
  1,008
  1,102
  1,200
  1,301
  1,407
  1,517
  1,631
  1,750
  1,874
  2,002
  2,135
Working capital, $m
  -11
  -15
  -21
  -27
  -34
  -43
  -54
  -65
  -78
  -93
  -109
  -127
  -146
  -166
  -188
  -211
  -235
  -261
  -288
  -316
  -345
  -376
  -407
  -440
  -475
  -511
  -548
  -587
  -627
  -668
Total debt, $m
  52
  82
  120
  166
  221
  286
  361
  447
  543
  650
  768
  896
  1,035
  1,183
  1,342
  1,510
  1,688
  1,875
  2,072
  2,277
  2,491
  2,715
  2,948
  3,190
  3,441
  3,703
  3,975
  4,257
  4,551
  4,856
Total liabilities, $m
  82
  112
  150
  196
  251
  316
  391
  477
  573
  680
  798
  926
  1,065
  1,214
  1,372
  1,541
  1,719
  1,906
  2,102
  2,307
  2,522
  2,745
  2,978
  3,220
  3,472
  3,733
  4,005
  4,287
  4,581
  4,886
Total equity, $m
  9
  12
  17
  22
  28
  35
  43
  53
  64
  76
  89
  103
  118
  135
  152
  171
  191
  212
  234
  256
  280
  305
  331
  358
  386
  415
  445
  476
  509
  543
Total liabilities and equity, $m
  91
  124
  167
  218
  279
  351
  434
  530
  637
  756
  887
  1,029
  1,183
  1,349
  1,524
  1,712
  1,910
  2,118
  2,336
  2,563
  2,802
  3,050
  3,309
  3,578
  3,858
  4,148
  4,450
  4,763
  5,090
  5,429
Debt-to-equity ratio
  5.670
  6.560
  7.180
  7.610
  7.910
  8.140
  8.300
  8.430
  8.520
  8.600
  8.660
  8.700
  8.740
  8.770
  8.800
  8.820
  8.840
  8.860
  8.870
  8.880
  8.890
  8.900
  8.910
  8.920
  8.920
  8.930
  8.930
  8.940
  8.940
  8.940
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -1
  1
  2
  2
  3
  4
  5
  6
  7
  8
  12
  13
  14
  16
  17
  18
  19
  20
  22
  23
  24
  26
  27
  29
  30
  32
  33
  35
  37
  38
Depreciation, amort., depletion, $m
  6
  6
  7
  7
  8
  9
  10
  11
  13
  14
  12
  13
  16
  18
  20
  22
  25
  28
  31
  34
  37
  40
  43
  47
  51
  54
  58
  62
  67
  71
Funds from operations, $m
  4
  7
  8
  10
  11
  13
  15
  17
  20
  22
  24
  27
  30
  33
  37
  40
  44
  48
  52
  57
  61
  66
  70
  75
  81
  86
  92
  97
  103
  110
Change in working capital, $m
  -3
  -4
  -5
  -6
  -8
  -9
  -10
  -12
  -13
  -15
  -16
  -18
  -19
  -20
  -22
  -23
  -24
  -26
  -27
  -28
  -29
  -31
  -32
  -33
  -34
  -36
  -37
  -39
  -40
  -42
Cash from operations, $m
  8
  11
  13
  16
  19
  22
  25
  29
  33
  37
  40
  44
  49
  54
  58
  63
  69
  74
  79
  85
  90
  96
  102
  109
  115
  122
  129
  136
  144
  151
Maintenance CAPEX, $m
  -1
  -1
  -2
  -2
  -3
  -4
  -5
  -6
  -7
  -8
  -10
  -12
  -13
  -16
  -18
  -20
  -22
  -25
  -28
  -31
  -34
  -37
  -40
  -43
  -47
  -51
  -54
  -58
  -62
  -67
New CAPEX, $m
  -10
  -13
  -16
  -20
  -24
  -28
  -33
  -37
  -42
  -47
  -51
  -56
  -61
  -65
  -69
  -74
  -78
  -82
  -86
  -90
  -94
  -98
  -102
  -106
  -110
  -114
  -119
  -123
  -128
  -133
Cash from investing activities, $m
  -11
  -14
  -18
  -22
  -27
  -32
  -38
  -43
  -49
  -55
  -61
  -68
  -74
  -81
  -87
  -94
  -100
  -107
  -114
  -121
  -128
  -135
  -142
  -149
  -157
  -165
  -173
  -181
  -190
  -200
Free cash flow, $m
  -3
  -3
  -5
  -6
  -8
  -10
  -12
  -14
  -16
  -18
  -21
  -23
  -25
  -27
  -29
  -30
  -32
  -33
  -34
  -36
  -37
  -38
  -39
  -41
  -42
  -43
  -44
  -46
  -47
  -49
Issuance/(repayment) of debt, $m
  2
  30
  38
  46
  55
  65
  75
  86
  96
  107
  118
  128
  139
  149
  159
  168
  178
  187
  196
  205
  214
  223
  233
  242
  252
  262
  272
  282
  294
  305
Issuance/(repurchase) of shares, $m
  24
  2
  3
  3
  3
  3
  4
  4
  4
  4
  1
  1
  1
  1
  1
  1
  1
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  26
  32
  41
  49
  58
  68
  79
  90
  100
  111
  119
  129
  140
  150
  160
  169
  179
  187
  196
  205
  214
  223
  233
  242
  252
  262
  272
  282
  294
  305
Total cash flow (excl. dividends), $m
  23
  29
  35
  42
  50
  58
  66
  75
  84
  93
  97
  106
  114
  123
  131
  139
  147
  154
  162
  170
  177
  185
  193
  201
  210
  218
  227
  237
  246
  256
Retained Cash Flow (-), $m
  -24
  -3
  -4
  -5
  -6
  -7
  -8
  -10
  -11
  -12
  -13
  -14
  -15
  -17
  -18
  -19
  -20
  -21
  -22
  -23
  -24
  -25
  -26
  -27
  -28
  -29
  -30
  -31
  -33
  -34
Prev. year cash balance distribution, $m
  77
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  76
  26
  31
  37
  44
  51
  58
  66
  73
  81
  84
  92
  99
  106
  113
  120
  127
  134
  140
  147
  154
  161
  167
  175
  182
  189
  197
  205
  214
  223
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  73
  24
  27
  31
  34
  37
  39
  41
  42
  42
  40
  39
  38
  36
  33
  31
  28
  25
  22
  19
  16
  13
  11
  9
  7
  6
  4
  3
  2
  2
Current shareholders' claim on cash, %
  50.0
  48.3
  46.9
  45.8
  44.9
  44.2
  43.6
  43.0
  42.6
  42.2
  42.2
  42.1
  42.0
  42.0
  41.9
  41.9
  41.9
  41.9
  41.9
  41.9
  41.9
  41.9
  41.9
  41.9
  41.9
  41.9
  41.9
  41.9
  41.9
  41.9

Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company's pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools. It also includes commercial product, RELISTOR (methylnaltrexone bromide) for opioid-induced constipation. AZEDRA is a radiotherapeutic product candidate in development as a treatment for malignant and/or recurrent pheochromocytoma and paraganglioma, rare tumors found in the adrenal glands and outside of the adrenal glands, respectively. RELISTOR is a treatment for opioid induced constipation. PyL is a clinical-stage, fluorinated PSMA-targeted Positron Emission Topography (PET) imaging agent for prostate cancer. PSMA TTC is a thorium-227 labeled PSMA-targeted antibody therapeutic.

FINANCIAL RATIOS  of  Progenics Pharmaceuticals (PGNX)

Valuation Ratios
P/E Ratio 33.8
Price to Sales 5.4
Price to Book 3.5
Price to Tangible Book
Price to Cash Flow 19.6
Price to Free Cash Flow 24.8
Growth Rates
Sales Growth Rate 666.7%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio 0.3
LT Debt to Equity 46.7%
Total Debt to Equity 46.7%
Interest Coverage 0
Management Effectiveness
Return On Assets 6.7%
Ret/ On Assets - 3 Yr. Avg. -5.7%
Return On Total Capital 9%
Ret/ On T. Cap. - 3 Yr. Avg. -7.8%
Return On Equity 11.3%
Return On Equity - 3 Yr. Avg. -7%
Asset Turnover 0.4
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 33.3%
EBITDA Margin 21.7%
EBITDA Margin - 3 Yr. Avg. -130.5%
Operating Margin 18.8%
Oper. Margin - 3 Yr. Avg. -135.9%
Pre-Tax Margin 18.8%
Pre-Tax Margin - 3 Yr. Avg. -135.9%
Net Profit Margin 15.9%
Net Profit Margin - 3 Yr. Avg. -136.1%
Effective Tax Rate 15.4%
Eff/ Tax Rate - 3 Yr. Avg. -6%
Payout Ratio 0%

PGNX stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the PGNX stock intrinsic value calculation we used $11.698 million for the last fiscal year's total revenue generated by Progenics Pharmaceuticals. The default revenue input number comes from 0001 income statement of Progenics Pharmaceuticals. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our PGNX stock valuation model: a) initial revenue growth rate of 40.3% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for PGNX is calculated based on our internal credit rating of Progenics Pharmaceuticals, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Progenics Pharmaceuticals.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of PGNX stock the variable cost ratio is equal to 91.7%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for PGNX stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 8.6% for Progenics Pharmaceuticals.

Corporate tax rate of 27% is the nominal tax rate for Progenics Pharmaceuticals. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the PGNX stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for PGNX are equal to 218.5%.

Life of production assets of 42.8 years is the average useful life of capital assets used in Progenics Pharmaceuticals operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for PGNX is equal to -68.4%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $63.453 million for Progenics Pharmaceuticals - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 84.45 million for Progenics Pharmaceuticals is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Progenics Pharmaceuticals at the current share price and the inputted number of shares is $0.4 billion.

RELATED COMPANIES Price Int.Val. Rating
NKTR Nektar Therape 38.19 107.89  str.buy
JNJ Johnson&Johnso 144.50 176.79  buy
MRK Merck&Co 74.84 33.05  str.sell
MCRB Seres Therapeu 8.21 0.37  str.sell

COMPANY NEWS

▶ Progenics: 3Q Earnings Snapshot   [08:49AM  Associated Press]
▶ Qualcomm and Tailored Brands rise; Kroger stumbles   [Sep-13-18 04:28PM  Associated Press]
▶ After-hours buzz: PVTL, PGNX & more   [Sep-12-18 05:21PM  CNBC]
▶ Progenics: 2Q Earnings Snapshot   [Jul-31-18 07:17PM  Associated Press]
▶ FDA approves first non-surgical treatment for 2 rare cancers   [11:40AM  American City Business Journals]
▶ 3 Stocks That Could Double Your Money   [Jul-26-18 08:57AM  Motley Fool]
▶ 3 Biotech Stocks With Major Catalysts Incoming   [Jul-03-18 09:31AM  Motley Fool]
▶ 4 Drug and Biotech Stocks Awaiting FDA Decisions in July   [Jul-02-18 03:23PM  InvestorPlace]
▶ 3 Biotech Stocks With Major Potential Catalysts in July   [Jun-27-18 06:01AM  Motley Fool]
▶ 5 Stocks in Focus on New Analyst Coverage   [May-21-18 10:09AM  Zacks]
▶ Progenics: 1Q Earnings Snapshot   [May-09-18 08:34AM  Associated Press]
▶ 3 Hot Junior Biotech Plays   [Mar-16-18 10:10AM  Investopedia]
▶ 5 Stocks That Are Showing Signs of Reversing   [Mar-12-18 02:00PM  TheStreet.com]
▶ Why Progenics Pharmaceuticals Jumped 15.2% on Thursday   [Mar-08-18 05:49PM  Motley Fool]
▶ Progenics reports 4Q loss   [10:11AM  Associated Press]
▶ Goldman Sachs and Hess slide while PepsiCo and TiVo rise   [Dec-29-17 05:22PM  Associated Press]
▶ Progenics Pharma Surges on FDA Decision   [09:50AM  24/7 Wall St.]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.